




RealRate

PHARMACEUTICAL 2021

Corbus Pharmaceuticals Holdings Inc. Rank 311 of 402





RealRate

PHARMACEUTICAL 2021

Corbus Pharmaceuticals Holdings Inc. Rank 311 of 402



The relative strengths and weaknesses of Corbus Pharmaceuticals Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corbus Pharmaceuticals Holdings Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Corbus Pharmaceuticals Holdings Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is -42%, being 89% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	92,075
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31,898
Liabilities, Non-Current	25,122
Other Assets	6,152
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	11,541
Other Revenues	3,937
Property and Equipment	4,068
Research and Development	98,267
Selling, General and Administrative Expense	28,480

Output Variable	Value in 1000 USD
Assets	102,295
Liabilities	57,020
Expenses	126,747
Revenues	3,937
Stockholders Equity	45,275
Net Income	-111,269
Comprehensive Net Income	-111,269
Economic Capital Ratio	-42%